AUTHOR AND EDITOR INFORMATION

Section 1 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

OCD, obsessive-compulsive disorder, depression, antidepressants, anxiety, anxiety disorders, insomnia, sleep disorders, panic disorder, estrogen-related sleep disturbance, weight gain, mood changes, lability

FSH, follicle-stimulating hormone, luteinizing hormone, LH, estrogen, androstenedione, gonadotropin-releasing hormone, GnRH, hormone replacement therapy, HRT, estrogen replacement therapy, ERT

INTRODUCTION

Section 2 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

Background

Menopause is considered to occur when 12 menstrual cycles are missed.^{1, 2} Perimenopause, or menopausal transition, is defined as the time from the onset of the climacteric through the first year after last menses.³ Perimenopause is characterized by menstrual irregularities, prolonged and heavy menstruation intermixed with episodes of amenorrhea, decreased fertility, vasomotor symptoms, and insomnia. Some of these symptoms may emerge 4 years before menses cease, with a mean age of onset of perimenopause of 47.5 years.⁴ During the menopausal transition, estrogen levels decline, and levels of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) increase.

Depression during menopause

In the United States, 1.3 million women reach menopause annually. Although most women transition to menopause without experiencing psychiatric problems, an estimated 20% have depression at some point during menopause.⁵

Studies of mood during menopause have generally revealed an increased risk of depression during perimenopause.

In a cross-sectional population survey from the Netherlands, 2103 women were asked to rate their symptoms of depression before menopause and 3.5 years later, during the menopausal transition. The women experienced most symptoms of depression during the menopausal transition. In the United States, a study of a community sample of women undergoing natural menopause also demonstrated an increase in depressive symptoms during perimenopause.⁶

Investigators from the Harvard Study of Moods and Cycles recruited premenopausal women aged 36-44 years with no history of major depression and followed up these women for 9 years to detect new onsets of major depression. Women who entered perimenopause were twice as likely as women who had not yet made the menopausal transition to have clinically significant depressive symptoms.⁷

Problems with sleep during menopause

Insomnia occurs in 40-50% of women during the menopausal transition, and problems with sleep may or may not be connected to mood disorders.⁸ Women with insomnia are more likely than others to report problems such as anxiety, stress, tension, and depressive symptoms. Whether the sleep problems are associated with age-related changes in sleep architecture, hormonal status, or other symptoms of menopause (eg, vasomotor symptoms) is unclear. Many authors have suggested that hot flashes are to blame for patients' sleep problems; however, results of polysomnographic studies have been inconclusive.

Rates of sleep apnea increase with age, rising from 6.5% in women aged 30-39 years to 16% in women aged 50-60 years. The pathophysiology is not known, but theories include a relationship to postmenopausal weight gain or to decreased progesterone levels because progesterone stimulates respiration.^{9, 10} In addition to undergoing changes in estrogen and progesterone levels, postmenopausal women experience a decline in melatonin and growth hormone levels, both of which have effects on sleep.¹¹

Schizophrenia during menopause

In most cases, schizophrenia first manifests in young adulthood, with the rate of new cases declining in both male and female individuals after early adulthood. A second peak in the incidence of schizophrenia is noted among women aged 45-50 years; this second peak is not observed in men.¹²

Some researchers have observed a worsening of the course of schizophrenia in women during the menopausal transition. These observations may suggest that estrogen plays a modulatory role in the pathophysiology of schizophrenia.¹³

Panic disorder during menopause

Panic disorder is common during perimenopause. New-onset panic disorder may occur during menopause, or preexisting panic disorder may worsen. Panic disorder may be most common in women with many physical symptoms of menopause.¹⁴

Obsessive-compulsive disorder during menopause

New-onset obsessive-compulsive disorder (OCD), a relapse of OCD, or a change in OCD symptoms may occur during menopause. Fluctuations in OCD have been correlated with the menstrual cycle and with pregnancy, suggesting that hormone levels may contribute to the disorder.¹⁵

Bipolar disorder during menopause

Exacerbation of mood symptoms during menopause has been noted in women with preexisting bipolar disorder—especially with a worsening of depression and, perhaps, an increase in rapid cycling during the menopausal transition.^{16, 17}

Pathophysiology

Depression during perimenopause is likely due to fluctuating and declining estrogen levels in part. Steroid hormones, such as estrogen, act in the CNS by means of various mechanisms. For instance, they stimulate the synthesis of neurotransmitters, the expression of receptors, and influence membrane permeability.¹⁸

Estrogen increases the effects of serotonin and norepinephrine, which are thought to be the neurotransmitters most related to the physiologic cause of depression. Among other mechanisms, estrogen decreases monoamine oxidase (MAO) activity in the CNS, hindering the break down of serotonin and norepinephrine are not broken down as readily.² In addition, estrogen increases serotonin synthesis, upregulates 5-hydroxytryptamine (5-HT)-1 (5-HT1) receptors, and downregulates 5-HT2 receptors. Estrogen also increases norepinephrine activity in the brain, perhaps by decreasing reuptake and degradation due to inhibition of the enzymes MAO and catechol O-methyltransferase.¹⁹

Although the precise mechanisms are yet unknown, regulation or serotonin and norepinephrine may change as estrogen levels fluctuate and thus contribute to depression. Because estrogen facilitates the actions of serotonin and norepinephrine, a decline in estrogen concentrations may, in turn, decrease levels of these hormones.^{2, 18, 19} Changes in estrogen levels, perhaps due to mechanisms involving these neurotransmitters, may be related to depressive symptoms in the menopausal transition of some women.

Frequency

United States

Each year, 1.3 million women reach menopause. An estimated 20% of these women experience depression.⁵

Mortality/Morbidity

Although morbidity and mortality secondary to perimenopausal depression has not been studied, depression is known to be a significant health problem in women. According to the World Health Organization's Global Burden of Disease Study, unipolar depression is the leading cause of disease-related disability in women.²⁰ In the Global Burden of Disease Study, unipolar major depression was second to only ischemic heart disease in terms of associated morbidity and mortality.²¹

Race

The racial distribution of perimenopausal depression is not known. However, in countries where older women are highly valued, women experience fewer symptoms overall during menopause.

Sex

Depression is approximately twice as common in women as in men (21% vs 12.7%). Moreover, depressive are more recurrent, longer, worse, and more impairing for women and for men.^{22, 23} In addition, the prevalence of dysthymia and minor depression is increases among women. These differences have not been noted for mania. Sex-related differences emerge at the age of 11-15 years.²⁰

Age

The mean age of onset for the menopausal transition is 47.5 years.⁴

CLINICAL

Section 3 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

History

• Perimenopause
  • Hot flashes
  • Cold sweats
  • Irregular menstrual bleeding
  • Urogenital atrophy and dryness with resultant dyspareunia (see gynecologic pain), itching, and urinary urge incontinence
  • Cognitive and affective disturbance
• Major depression
• • Depressed mood
  • Decreased interest or pleasure in activities
  • Increased or decreased appetite
  • Weight change
  • Insomnia or hypersomnia
  • Psychomotor agitation or retardation
  • Feelings of worthlessness or guilt
  • Decreased concentration
  • Indecisiveness
  • Suicidal ideation and plans
  • Homicidal thoughts and plans
• Depression, with the following suggestive features from a mental status examination:
• • Motor retardation
  • Latency of response to questions
  • Slowed thought process
  • Diminished prosody of speech
  • Poor eye contact
  • Poor grooming or hygiene (may indicate advanced depression

Physical

Findings of perimenopause include urogenital atrophy, as well as flushing and diaphoresis during hot flashes.

Causes

Causes of menopause-related mood disorders may include hormonal changes, life stressors, psychological or social conditions, and/or a preexisting tendency to develop depression.

Hormonal changes

Depression seems to be significantly linked to times of hormonal change in women. Several observations and study data support this theory. For example, the disparity between rates of depression in women and men begins at puberty. Also, hormonal changes are thought to be major contributors to premenstrual dysphoric disorder, as well as mood changes experienced in the postpartum period and at the menopausal transition.^{22, 23} Furthermore, estrogen affects both serotonin and norepinephrine, the 2 neurotransmitters thought to be most directly associated with depression.

Of note, absolute levels of gonadal hormones are not correlated with depression. Estrogen and progesterone levels do not distinguish a woman with depression from one without depression. When hormone concentrations were measured in perimenopausal or postmenopausal women with depression, no abnormal levels were found.²⁴ Rather, a certain subset of women seem to be predisposed to have mood disturbances triggered by hormonal fluctuations. This subset includes women with a history of mood disorders or of premenstrual and postpartum mood-related symptoms. The risk of depression appears to be higher during perimenopause, when hormone levels are changing, than during postmenopause, when estrogen and progesterone levels are low but stable.^{18, 25}

Life stressors

Societal roles and expectations may contribute to the heightened rate of depression in women. Women with particular types of stressors seem to be at increased risk for perimenopausal depression. Such stressors include the following^{5, 23}:

• Lack of social support
• Unemployment
• Surgical menopause
• Poor overall health status

Dysphoric mood during the early perimenopausal transition is most common in women with relatively low educational status. Therefore, low levels of education may be a marker for other stressors, such as ongoing low socioeconomic status.²⁶

An Australian study of women transitioning to menopause revealed more depression in women with the following states²⁷:

• Negative mood before menopause
• Negative attitude toward menopause and aging
• Smoking
• Little or no exercise
• No partner
• A number of bothersome symptoms
• Poor self-perceived health
• Negative feelings toward partner
• A number of perceived problems
• Interpersonal stress

Other stressors that tend to correspond with perimenopause and that are postulated to relate to depression include the following:

• Onset of illness in self or others
• Care of aging parents
• Changes in employment

Psychological or social conditions

Numerous psychological and social theories have been proffered to explain why women may become depressed during perimenopause. Some of these are related to the following factors:

• Change in the childbearing role
• Loss of fertility, which may be associated with a loss of an essential meaning of life
• Empty-nest syndrome (However, surveys have indicated that women whose children have moved out of the house tend to report more happiness and enjoyment in life than do others.)
• Societal value of youth (In societies where age is valued, women tend to report having fewer symptoms at the menopause transition.)

Preexisting tendency to develop depression

A personal or family history of major depression, postpartum depression, or premenstrual dysphoric disorder seem to be a major risk factor for depression in the perimenopausal period.⁵ However, perimenopausal depressive syndrome is a risk even in women without a history of depression.

DIFFERENTIALS

Section 4 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

Other Problems to be Considered

Dementia
Depression secondary to a general medical condition
Endocrine disorders (eg, hypothyroid)
Substance abuse
Use of medications, such as beta-blockers

WORKUP

Section 5 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

Lab Studies

• Thyroid-stimulating hormone (TSH) determination: Monitor patients for hypothyroidism because thyroid disease is an independent risk factor for depression in menopausal women.⁶
• FSH and LH measurements: Because ovarian production of inhibin and estrogen declines during perimenopause (see Ovarian Insufficiency), FSH and, later, LH levels begin to increase. An FSH level >40 IU/L is often used as a marker of menopausal changes. Patients may begin to notice changes before laboratory values reflect the changes.
• Hematocrit test: Anemia can be associated with depressive-type symptoms.

Other Tests

A mental status examination must be performed (see History and Mental Status Examination).

TREATMENT

Section 6 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

Medical Care

Treatment of perimenopausal depression

For major depression, standard antidepressants are first-line treatments. Selective serotonin reuptake inhibitors (SSRIs) are the most common ones. The onset of action is 4-6 weeks.

Although results from studies of hormone treatments for depression have been inconsistent, such treatments have been helpful for managing depressive symptoms in perimenopause but not postmenopause.^{4, 13}

For mild depression, hormone replacement therapy alone may be appropriate. Estrogen may be used when traditional antidepressants failed, when patients refuse psychotropic medications, or when patients experience other clinically significant vasomotor symptoms.^{13, 28}

Treatment of hot flashes

SSRIs are sometimes used to treat hot flashes. Paroxetine, paroxetine CR, and venlafaxine ER may provide some benefit.^{3, 29} Clonidine and gabapentin have been shown to reduce hot flashes.²⁹

Treatment of sleep disorders

Estrogen may be helpful in relieving vasomotor symptoms that disrupt sleep or that may have a direct effect on sleep itself.¹⁰

In a study of postmenopausal women with hot flashes, night sweats, insomnia, anxiety, and/or mood swings, low-dose estrogen and low-dose micronized progesterone improved sleep to a greater extent than could be explained by a reduction in vasomotor symptoms.³⁰

Maintenance of cognitive function

Data from observational studies suggest that estrogen may prevent or delay the onset of dementia, including Alzheimer disease, especially when estrogen therapy started in young postmenopausal women.¹³

The data do not suggest that estrogen is helpful for cognitive function in all perimenopausal and postmenopausal women. The Women's Health Initiative Memory Study (WHIMS) was a study of postmenopausal women older than 65 years who were unlikely to have preexisting dementia. The women were monitored by means of serial mini–mental status examinations. No improvement in global cognitive functioning was observed with estrogen treatment.³¹

Group therapy

Negative anticipation of menopause seems to be associated with elevated rates of depression and physical symptoms of menopause. Educational groups that help women learn what to expect during menopause decrease anxiety, depression, and irritability, both immediately after the group therapy and 1 year later.³²

Psychiatric hospitalization

Psychiatric hospitalization is indicated for patients who are at imminent risk of harming themselves or others and for those whose depressive symptoms render them unable to care for themselves.

Surgical Care

Women who have surgically induced menopause have an increased risk of depression,³³ and they may be especially likely to benefit from hormone replacement therapy.

Consultations

Primary care providers, gynecologists, and psychiatrists often find it helpful to work collaboratively.

Diet

A healthy, balanced diet is advisable.

Activity

Regular exercise is thought to be helpful in diminishing the symptoms of depression.

MEDICATION

Section 7 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

Hormone treatment for depressed perimenopausal women

Data from several studies suggested that estrogen replacement therapy had antidepressant effects or that it enhanced the effects of antidepressant treatment in perimenopausal women.^{28, 34, 35, 36, 37, 38} Other studies did not show that estrogen adds to the effects of SSRIs.^{37, 39}

Debate exists regarding whether the antidepressant effect is attributable to the effect of estrogen on vasomotor symptoms. Some studies reveal an antidepressant benefit only in women with vasomotor symptoms. Results of other studies suggest an independent antidepressant effect.^{40, 41} Although perimenopausal women may benefit from estrogen replacement, postmenopausal women may not.⁴²

Hormone treatment to enhance mood and quality of life in nondepressed perimenopausal women

The effects of estrogen treatment have been studied in perimenopausal women without depression to see if it has a positive effect on mood or quality of life. Results from small studies have suggested a small positive impact on mood.^{30, 43} However, most data suggest that, among healthy women without depression, estrogen has no favorable effect on quality of life or mood.^{40, 44, 45}

Antidepressant treatment for depressed perimenopausal women

SSRIs are the antidepressants most commonly used in the treatment of perimenopausal depression. These drugs act by inhibiting serotonin reuptake transporters in the presynaptic neuron, making more serotonin available at the synaptic cleft.

SSRIs are thought to be generally safe and effective. They do pose a risk of serotonin syndrome, as well as several common adverse effects such as GI effects (nausea, diarrhea, anorexia), excessive sweating, decreased libido and/or anorgasmia, headache, jitteriness, dizziness, sedation or activation, insomnia, and akathisia. Several of these medications inhibit the cytochrome P450 (CYP) enzymes; therefore, it is prudent to check for drug interactions.

Antidepressant treatment for nondepressed perimenopausal women

In women with mild mood-disorder symptoms that do not meet the criteria for depression, hormone replacement therapy may be considered. Hormone replacement therapy may also be an adjunctive treatment for women with perimenopausal depression and prominent vasomotor symptoms.

Drug Category: SSRIs

SSRIs enhance the availability of serotonin and may improve both mood and physical symptoms associated with menopause. All SSRIs are equally effective, though responses and adverse effects may vary among individual patients.

Drug Category: Estrogen replacement

In women with mild mood-disorder symptoms not meeting the criteria for depression, hormone replacement therapy may be considered. Hormone replacement therapy may also be an adjunctive treatment for women with perimenopausal depression and prominent vasomotor symptoms.

FOLLOW-UP

Section 8 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

In/Out Patient Meds

See the Medication section above.

Patient Education

Patients may benefit from learning that mood symptoms are not uncommon during menopause. Providing education about depressive symptoms can help women understand their experiences and recognize depression as a treatable illness. Family members may also benefit from learning about the symptoms of major depression and the association of its onset with the menopausal transition. This information may help them understand changes they observe in their family member.

Patients should be educated about emergency mental health services that are available in their area. They should be aware of how to access help if they have suicidal thoughts.

Listed below are some useful clinician and patient education resources, as well as sources of additional information and support:

• Menopause article in the Obstetrics/Gynecology section of the eMedicine journal
• Menopause Center from eMedicineHealth, which addresses numerous topics related the change of life, such as causes, symptoms, when to seek medical care, self-care at home, and prevention of problems associated with menopause
• Menopause Resource Center by Medscape Today from WebMD
• Menopause Health Center from WebMD
• Midlife Transitions: A Guide to Approaching Menopause available from the American College of Obstetricians and Gynecologists (ACOG)
• Menopause from Medline Plus, a service of the US National Library of Medicine and the NIH
• Menopause Age Page (also available in Spanish) from the NIH, National Institute on Aging
• NIH State-of-the Science Conference Statement on Management of Menopause-Related Symptoms
• Women's Health Initiative conducted by the Department of Health and Human Services, NIH, National Heart, Lung, and Blood Institute, including these pages:
• • Information for the Public: Questions and Answers About Estrogen-Plus-Progestin Hormone Therapy
  • Information for the Public: Facts About Menopausal Hormone Therapy
  • Health Recommendations for Postmenopausal Women based on results from the Women's Health Initiative and other studies
  • Information for Health Professionals about postmenopausal hormone therapy
• Menopause & Hormones informational materials (also available in Spanish) from the US Food and Drug Administration
• Understanding Menopause from the National Women's Health Information Center, US Department of Health and Human Services
• The North American Menopause Society (NAMS)
• Menopause Support Group message boards hosted by WebMD

MISCELLANEOUS

Section 9 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

Medical/Legal Pitfalls

Carefully weigh the risks of estrogen treatment (see Medication).

REFERENCES

Section 10 of 10

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

1. Sherwin B. Menopause: myths and realities. In: Stotland NL, Stewart DE, eds. Psychological Aspects of Women's Health Care: The Interface Between Psychiatry and Obstetrics and Gynecology. 2^nd ed. Arlington, Va: American Psychiatric Publishing; 2001:241-59.
2. Spinelli MG. Depression and hormone therapy. Clin Obstet Gynecol. Jun 2004;47(2):428-36. [Medline].
3. National Institutes of Health. National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms. Ann Intern Med. Jun 21 2005;142(12 Pt 1):1003-13. [Medline].
4. Baram D. Physiology and symptoms of menopause. In: Steward DE, Robinson GE, eds. A Clinician's Guide to Menopause. Washington, DC: Health Press International; 1997:9-28.
5. Soares CN. Perimenopause-related mood disturbance: an update on risk factors and novel treatment strategies available. In: Meeting Program and Abstracts. Psychopharmacology and Reproductive Transitions Symposium. American Psychiatric Association 157th Annual Meeting; May 1-6, 2004; New York, NY. Arlington, Va: American Psychiatric Publishing; 2004:51-61.
6. Maartens LW, Knottnerus JA, Pop VJ. Menopausal transition and increased depressive symptomatology: a community based prospective study. Maturitas. Jul 25 2002;42(3):195-200. [Medline].
7. Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles. Arch Gen Psychiatry. Apr 2006;63(4):385-90. [Medline].
8. Soares CN, Joffe H, Steiner M. Menopause and mood. Clin Obstet Gynecol. Sep 2004;47(3):576-91.
9. Krystal AD. Depression and insomnia in women. Clin Cornerstone. 2004;6 Suppl 1B:S19-28. [Medline].
10. Miller EH. Women and insomnia. Clin Cornerstone. 2004;6 Suppl 1B:S8-18. [Medline].
11. Shin K, Shapiro C. Menopause, sex hormones, and sleep. Bipolar Disord. Apr 2003;5(2):106-9. [Medline].
12. Häfner H. Gender differences in schizophrenia. Psychoneuroendocrinology. Apr 2003;28 Suppl 2:17-54. [Medline].
13. Genazzani AR, Gambacciani M, Simoncini T, Schneider HP. Hormone replacement therapy in climacteric and aging brain. International Menopause Society Expert Workshop, 15-18 March 2003, Pisa, Italy. Climacteric. Sep 2003;6(3):188-203. [Medline].
14. Claudia P, Andrea C, Chiara C, Stefano L, Giuseppe M, Vincenzo DL. Panic disorder in menopause: a case control study. Maturitas. Jun 15 2004;48(2):147-54. [Medline].
15. Lochner C, Hemmings SM, Kinnear CJ, Moolman-Smook JC, Corfield VA, Knowles JA. Corrigendum to "gender in obsessive-compulsive disorder: clinical and genetic findings" [Eur Neuropsychopharmacol 14 (2004) 105-13]. Eur Neuropsychopharmacol. Oct 2004;14(5):437-45. [Medline].
16. Barnes C, Mitchell P. Considerations in the management of bipolar disorder in women. Aust N Z J Psychiatry. Aug 2005;39(8):662-73. [Medline].
17. Burt VK, Rasgon N. Special considerations in treating bipolar disorder in women. Bipolar Disord. Feb 2004;6(1):2-13. [Medline].
18. Steiner M, Dunn E, Born L. Hormones and mood: from menarche to menopause and beyond. J Affect Disord. Mar 2003;74(1):67-83. [Medline].
19. Halbreich U. Role of estrogen in postmenopausal depression. Neurology. May 1997;48(5 Suppl 7):S16-9. [Medline].
20. Kessler RC. Epidemiology of women and depression. J Affect Disord. Mar 2003;74(1):5-13. [Medline].
21. Michaud CM, Murray CJ, Bloom BR. Burden of disease--implications for future research. JAMA. Feb 7 2001;285(5):535-9. [Medline].
22. Huttner RP, Shepherd JE. Gonadal steroids, selective serotonin reuptake inhibitors, and mood disorders in women. Med Clin North Am. Sep 2003;87(5):1065-76. [Medline].
23. Sloan DM, Kornstein SG. Gender differences in depression and response to antidepressant treatment. Psychiatr Clin North Am. Sep 2003;26(3):581-94. [Medline].
24. Charney DA, Stewart DE. Psychiatric aspects. In: Steward DE, Robinson GE, eds. A Clinician's Guide to Menopause. Washington, DC: Health Press International; 1997:129-44.
25. Payne JL. The role of estrogen in mood disorders in women. Int Rev Psychiatry. Aug 2003;15(3):280-90. [Medline].
26. Bromberger JT, Assmann SF, Avis NE, Schocken M, Kravitz HM, Cordal A. Persistent mood symptoms in a multiethnic community cohort of pre- and perimenopausal women. Am J Epidemiol. Aug 15 2003;158(4):347-56. [Medline].
27. Dennerstein L, Lehert P, Burger H, Dudley E. Mood and the menopausal transition. J Nerv Ment Dis. Nov 1999;187(11):685-91. [Medline].
28. Klaiber EL, Broverman DM, Vogel W, Kobayashi Y. Estrogen therapy for severe persistent depressions in women. Arch Gen Psychiatry. May 1979;36(5):550-4. [Medline].
29. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA. Jun 4 2003;289(21):2827-34. [Medline].
30. Gambacciani M, Ciaponi M, Cappagli B, Monteleone P, Benussi C, Bevilacqua G. Effects of low-dose, continuous combined hormone replacement therapy on sleep in symptomatic postmenopausal women. Maturitas. Feb 14 2005;50(2):91-7. [Medline].
31. Espeland MA, Rapp SR, Shumaker SA, Brunner R, Manson JE, Sherwin BB. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA. Jun 23 2004;291(24):2959-68. [Medline].
32. Robinson GE, Stirtzinger R. Psychoeducational programs and support groups at transition to menopause. In: Steward DE, Robinson GE, eds. A Clinician's Guide to Menopause. Washington, DC: Health Press International; 1997:165-80.
33. Dennerstein L, Guthrie JR, Clark M, Lehert P, Henderson VW. A population-based study of depressed mood in middle-aged, Australian-born women. Menopause. Sep-Oct 2004;11(5):563-8. [Medline].
34. Gregoire AJ, Kumar R, Everitt B, Henderson AF, Studd JW. Transdermal oestrogen for treatment of severe postnatal depression. Lancet. Apr 6 1996;347(9006):930-3. [Medline].
35. Schmidt PJ, Nieman L, Danaceau MA, Tobin MB, Roca CA, Murphy JH. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol. Aug 2000;183(2):414-20. [Medline].
36. Schneider MA, Brotherton PL, Hailes J. The effect of exogenous oestrogens on depression in menopausal women. Med J Aust. Jul 30 1977;2(5):162-3. [Medline].
37. Schneider HP. Cross-national study of women's use of hormone replacement therapy (HRT) in Europe. Int J Fertil Womens Med. 1997;42 Suppl 2:365-75. [Medline].
38. Zweifel JE, O'Brien WH. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology. Apr 1997;22(3):189-212. [Medline].
39. Amsterdam J, Garcia-España F, Fawcett J, Quitkin F, Reimherr F, Rosenbaum J. Fluoxetine efficacy in menopausal women with and without estrogen replacement. J Affect Disord. Sep 1999;55(1):11-7. [Medline].
40. Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P, Whooley MA,. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA. Feb 6 2002;287(5):591-7. [Medline].
41. Soares CN, Almeida OP, Joffe H, Cohen LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. Jun 2001;58(6):529-34. [Medline].
42. Cohen LS, Soares CN, Poitras JR, Prouty J, Alexander AB, Shifren JL. Short-term use of estradiol for depression in perimenopausal and postmenopausal women: a preliminary report. Am J Psychiatry. Aug 2003;160(8):1519-22. [Medline].
43. Schiff R, Bulpitt CJ, Wesnes KA, Rajkumar C. Short-term transdermal estradiol therapy, cognition and depressive symptoms in healthy older women. A randomised placebo controlled pilot cross-over study. Psychoneuroendocrinology. May 2005;30(4):309-15. [Medline].
44. Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med. May 8 2003;348(19):1839-54. [Medline].
45. Heinrich AB, Wolf OT. Investigating the effects of estradiol or estradiol/progesterone treatment on mood, depressive symptoms, menopausal symptoms and subjective sleep quality in older healthy hysterectomized women: a questionnaire study. Neuropsychobiology. 2005;52(1):17-23. [Medline].
46. American Psychiatric Association. DSM-IV-TR. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, Text Revision. Arlington, Va: American Psychiatric Association; 2000.
47. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. Apr 14 2004;291(14):1701-12. [Medline].
48. Labad J, Menchón JM, Alonso P, Segalàs C, Jiménez S, Vallejo J. Female reproductive cycle and obsessive-compulsive disorder. J Clin Psychiatry. Apr 2005;66(4):428-35; quiz 546. [Medline].
49. Loprinzi CL, Stearns V, Barton D. Centrally active nonhormonal hot flash therapies. Am J Med. Dec 19 2005;118 Suppl 12B:118-23. [Medline].
50. Mitchell JL, Walsh J, Wang-Cheng R, Hardman JL. Postmenopausal hormone therapy: a concise guide to therapeutic uses, formulations, risks, and alternatives. Prim Care. Dec 2003;30(4):671-96. [Medline].
51. Morrison MF, Kallan MJ, Ten Have T, Katz I, Tweedy K, Battistini M. Lack of efficacy of estradiol for depression in postmenopausal women: a randomized, controlled trial. Biol Psychiatry. Feb 15 2004;55(4):406-12. [Medline].
52. Rosenbaum JF, Arana GW, Hyman SE, et al. Handbook of Psychiatric Drug Therapy. 5^th ed. Philadelphia, Pa: Lippincott, Williams & Wilkins; 2005.
53. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. Jul 17 2002;288(3):321-33. [Medline].

Article Last Updated: Jan 7, 2008